Clinical trials are research studies that explore newer treatment strategies for patients who are no longer responding to current treatments or who are eligible for a new therapy approach.
Data collected throughout the course of a trial helps develop a deeper understanding of the disease continuum and depending upon your condition, we may recommend participation in a clinical trial.
Clinical trials differ from a doctor’s office visit where the goal is to diagnose and treat the disease with established therapies. Rather clinical trials use of new therapies, current treatments used in an innovative way, or new surgical procedures. An Institutional Review Board (IRB) approval is always obtained prior to activating a study weighing the risks and benefits of a study. The IRB ensures that the clinical trial is conducted in accordance with all federal, institutional, and ethical guidelines.
Ask one of our specialists if you are eligible for a clinical trial protocol.
Current Clinical Trials
Neflamapimod in Patients with Lewy Body Dementia
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB).
The INSYTE Study for Parkinson’s Disease
To examine the current disease progression of Parkinson’s disease psychosis (PDP), the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers (NCT03152292).
The PROSPECT Trial for Essential Tremor / CALA Health
This is an open-label study of the Cala TWO device with home usage for 3 months to assess for duration of effect over the course of the trial. The device is a non-invasive peripheral neurostimulator for essential tremor and the study is open to patients with mild, moderate, and severe essential tremor.